About: Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for ACS patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double blinded, placebo controlled randomized trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for ACS patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double blinded, placebo controlled randomized trial Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for ACS patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double blinded, placebo controlled randomized trial
Creator	Li, Jing Li, Yi Wang, Bing Han, Angiolillo, Dominick Chen, Shaoliang Han, Yaling Jing, Quanmin Qiao, Shubing Wang, Xiaozeng
Source	PMC
abstract	BACKGROUND: Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is the cornerstone for prevention ischemic events in patients with acute coronary syndromes (ACS) and undergoing percutaneous coronary intervention (PCI). However, the optimal antiplatelet strategy for ACS patients with both high bleeding and high ischemic risks is unclear. STUDY DESIGN: The Optimal antiPlatelet Therapy for patients with high Bleeding and Ischemic RISK (OPT-BIRISK) trial is a multicenter, double blinded, placebo controlled, randomized study designed to test the superiority of extended antiplatelet therapy with clopidogrel monotherapy compared with aspirin and clopidogrel for reduction of bleeding events in ACS patients with both high bleeding and high ischemic risks (“bi-risk”). A total of 7700 patients who completed 9- to 12-month DAPT after new generation drug eluting stent implantation for the treatment of ACS will be randomized to receive clopidogrel monotherapy or aspirin plus clopidogrel for 9 months, followed by aspirin monotherapy for 3 months. The primary end point is Bleeding Academic Research Consortium type 2, 3 or 5 bleedings at 9 months after randomization. The key secondary endpoint is major adverse cardiac and cerebral events at 9 months after randomization, defined as a composite of all-cause death, myocardial infarction, stroke or coronary artery revascularization. CONCLUSION: OPT-BIRISK is the first large scale, randomized trial aimed to explore the optimal antiplatelet strategy for bi-risk ACS patients after PCI in current clinical practice. The results will add evidence regarding de-escalation antiplatelet therapy for patients at special risk.
has issue date	2020-07-09(xsd:dateTime)
bibo:doi	10.1016/j.ahj.2020.07.005
has license	no-cc
sha1sum (hex)	717bd5c97594e405e8d7c83f1758b77a8630d0b5
schema:url	https://doi.org/10.1016/j.ahj.2020.07.005
resource representing a document's title	Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for ACS patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double blinded, placebo controlled randomized trial
has PubMed Central identifier	PMC7346838
schema:publication	Am Heart J
resource representing a document's body	covid:717bd5c97594e405e8d7c83f1758b77a8630d0b5#body_text
is schema:about of	named entity 'Elsevier' named entity 'clopidogrel' named entity 'patients' named entity 'FREE' named entity 'FUNDED' covid:arg/717bd5c97594e405e8d7c83f1758b77a8630d0b5 named entity 'atherothrombotic' named entity 'coronary artery' named entity 'clopidogrel' named entity 'ischemic' named entity 'antiplatelet therapy' named entity 'monotherapy' named entity 'aspirin' named entity 'randomized trial' named entity 'aspirin' named entity 'DAPT' named entity 'double blinded' named entity 'ACS' named entity 'DAPT' named entity 'log rank test' named entity 'Germany' named entity 'DAPT' named entity 'secondary endpoints' named entity 'monotherapy' named entity 'DAPT' named entity 'open-label' named entity 'left main' named entity 'clopidogrel' named entity 'Academic Research' named entity 'cerebral ischemic' named entity 'follow-up' named entity 'PCI' named entity 'PCI' named entity 'thrombosis' named entity 'gastrointestinal' named entity 'antiplatelet' named entity 'inclusion and exclusion criteria' named entity 'active' named entity 'database' named entity 'blinded' named entity 'randomized trial' named entity 'revascularization' named entity 'Shenyang' named entity 'Sanofi' named entity 'thrombosis' named entity 'ischemic' named entity 'secondary prevention' named entity 'Bayer' named entity 'ischemic' named entity 'all-cause' named entity 'Stroke' named entity 'cardiovascular' named entity 'coronary artery' named entity 'clopidogrel' named entity 'primary endpoint' named entity 'General Hospital' named entity 'P2Y12 inhibitor' named entity 'ischemic' named entity 'ischemic' named entity 'ischemic' named entity 'DAPT' named entity 'neurologic dysfunction' named entity 'antiplatelet agent' named entity 'anti-ischemic' named entity 'aspirin' named entity 'ischemic' named entity 'drug eluting stent' named entity 'cholesterol lowering' named entity 'DAPT' named entity 'heart failure' named entity 'ACS' named entity 'aspirin' named entity 'aspirin' named entity 'acute coronary syndromes'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software